Table 4 Baseline characteristics of patients in the different groups of treatments (NO ICS)
NO ICS (n = 334) | |||||
|---|---|---|---|---|---|
Tiotropium (n = 89) | Formoterol/Salmeterol (n = 49) | Indacaterol (n = 98) | Tiotropium+Indacaterol (n = 67) | Other (n = 31) | |
Gender (%F) | 28% | 25% | 28% | 33% | 36% |
Age (Yrs) | 72.0 (9.6) | 71.5 (8.1) | 71.4 (10.0) | 73.4 (9.7) | 71.7 (9.4) |
BMI | 27.4 (4.8) | 27.2 (4.8) | 27.5 (4.9) | 28.3 (5.6) | 28.0 (5.3) |
Smoking history° (%Y) | 79% | 78% | 84% | 86% | 83% |
Years since diagnosis | 5.4 (6.6) | 8.7 (8.6) | 7.3 (5.8) | 6.4 (6.3) | 7.2 (7.0) |
VC (%pred) | 96.1 (16.7) | 90.5 (15.9) | 91.2 (14.8) | 88.6 (14.9) | 89.4 (17.0) |
FEV 1 (%pred) | 75.2 (15.6) | 72.0 (8.2) | 72.8 (10.2) | 67.5 (6.9) | 68.1 (12.1) |
FEV 1 /VC | 0.61 (0.10) | 0.60 (0.08) | 0.60 (0.08) | 0.59 (0.08) | 0.59 (0.04) |
CAT | 13.8 (7.2) | 13.3 (5.8) | 14.7 (8.0) | 21.9 (9.2) | 15.0 (8.6) |
Exacerbations (0/1) | 35/54 | 13/36 | 33/65 | 31/36 | 10/21 |
Comorbidities: 0 | 31 (35%) | 20 (41%) | 32 (33%) | 17 (26%) | 6 (19%) |
Comorbidities: 1 | 23 (26%) | 16 (33%) | 27 (27%) | 24 (36%) | 10 (31%) |
Comorbidities: ≥2 | 35 (39%) | 13 (26%) | 39 (40%) | 26 (38%) | 15 (50%) |